Publications

Showing 3 of 3 Publications

2020

Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Greil R, Rischin D, Harrington K, Soulières D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Swaby R, Gumuscu B, Burtness B. Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s660-s661. DOI: 10.1016/j.annonc.2020.08.1030.
Peer-Reviewed Original Research
Concepts

2014

p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary
Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-1684. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2012

p16 Status, Pathologic and Clinical Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck
Keller L, Galloway T, Holdbrook T, Flieder D, Ruth K, Lango M, Mehra R, Burtness B, Ridge J. p16 Status, Pathologic and Clinical Characteristics, and Long-term Outcomes in Unknown Primary Carcinomas of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s514. DOI: 10.1016/j.ijrobp.2012.07.1370.
Peer-Reviewed Original Research
Concepts

Download Full List